Recent Advances in the Development of Antiviral Therapeutics for Rift Valley Fever Virus Infection

References

• Daubney R , HudsonJR, GarnhamPC . Enzootic hepatitis or rift valley fever. An undescribed virus disease of sheep cattle and man from East Africa . J. Pathol. Bacteriol.34 ( 4 ), 545 – 579 ( 1931 ).
   Google Scholar
• Bird BH , KsiazekTG, NicholST, MaclachlanNJ . Rift Valley fever virus . J. Am. Vet. Med. Assoc.234 ( 7 ), 883 – 893 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Linthicum KJ , BritchSC, AnyambaA . Rift Valley fever: an emerging mosquito-borne disease . Annu. Rev. Entomol.61, 395 – 415 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Fafetine JM , CoetzeeP, MubembaBet al. Rift Valley fever outbreak in livestock, Mozambique, 2014 . Emerg. Infect. Dis.22 ( 12 ), 2165 – 2167 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• El Mamy AB , LoMM, ThionganeYet al. Comprehensive phylogenetic reconstructions of Rift Valley fever virus: the 2010 northern Mauritania outbreak in the Camelus dromedarius species . Vector Borne Zoonotic Dis.14 ( 12 ), 856 – 861 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Sow A , FayeO, BaYet al. Rift Valley fever outbreak, southern Mauritania, 2012 . Emerg. Infect. Dis.20 ( 2 ), 296 – 299 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hassan OA , AhlmC, SangR, EvanderM . The 2007 Rift Valley fever outbreak in Sudan . PLoS Negl. Trop. Dis.5 ( 9 ), e1229 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Archer BN , WeyerJ, PaweskaJet al. Outbreak of Rift Valley fever affecting veterinarians and farmers in South Africa, 2008 . S. Afr. Med. J.101 ( 4 ), 263 – 266 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Jost CC , NzietchuengS, KihuSet al. Epidemiological assessment of the Rift Valley fever outbreak in Kenya and Tanzania in 2006 and 2007 . Am. J. Trop. Med. Hyg.83 ( 2 Suppl. ), 65 – 72 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Findlay GM , DaubneyR . The virus of Rift Valley fever or enzootic hepatitis . Lancet218 ( 5651 ), 1350 – 1351 ( 1931 ).
   Google Scholar
• Easterday BC . Rift Valley fever . Adv. Vet. Sci.10, 65 – 127 ( 1965 ).
   PubMedGoogle Scholar
• Daubney R , HudsonJR . Rift Valley fever . Lancet1, 611 – 612 ( 1932 ).
   Google Scholar
• Linthicum KJ , DaviesFG, KairoA, BaileyCL . Rift Valley fever virus (family Bunyaviridae, genus Phlebovirus). Isolations from Diptera collected during an interepizootic period in Kenya . J. Hyg. (Lond.)95 ( 1 ), 197 – 209 ( 1985 ).
   PubMedGoogle Scholar
• Britch SC , LinthicumKJ, The Rift Valley Fever Working Group . Developing a research agenda and a comprehensive national prevention and response plan for Rift Valley fever in the United States . Emerging Infect. Dis.13 ( 8 ), e1 ( 2007 ).
   PubMedGoogle Scholar
• Golnar AJ , KadingRC, HamerGL . Quantifying the potential pathways and locations of Rift Valley fever virus entry into the United States . Transbound. Emerg. Dis. doi:10.1111/tbed.12608 ( 2017 ) ( Epub ahead of print ).
   PubMed Web of Science ®Google Scholar
• Golnar AJ , TurellMJ, LabeaudAD, KadingRC, HamerGL . Predicting the mosquito species and vertebrate species involved in the theoretical transmission of Rift Valley fever virus in the United States . PLoS Negl. Trop. Dis.8 ( 9 ), e3163 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• House JA , TurellMJ, MebusCA . Rift Valley fever: present status and risk to the western hemisphere . Ann. NY Acad. Sci.653, 233 – 242 ( 1992 ).
   PubMed Web of Science ®Google Scholar
• Kasari TR , CarrDA, LynnTV, WeaverJT . Evaluation of pathways for release of Rift Valley fever virus into domestic ruminant livestock, ruminant wildlife, and human populations in the continental United States . J. Am. Vet. Med. Assoc.232 ( 4 ), 514 – 529 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Rolin AI , Berrang-FordL, KulkarniMA . The risk of Rift Valley fever virus introduction and establishment in the United States and European Union . Emerg. Microbes Infect.2 ( 12 ), e81 ( 2013 ).
   PubMedGoogle Scholar
• Liu J , SunY, ShiWet al. The first imported case of Rift Valley fever in China reveals a genetic reassortment of different viral lineages . Emerg. Microbes Infect.6 ( 1 ), e4 ( 2017 ).
   PubMedGoogle Scholar
• Liu W , SunFJ, TongYG, ZhangSQ, CaoWC . Rift Valley fever virus imported into China from Angola . Lancet Infect. Dis.16 ( 11 ), 1226 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Ikegami T . Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate . Expert Rev. Vaccines16 ( 6 ), 601 – 611 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Indran SV , IkegamiT . Novel approaches to develop Rift Valley fever vaccines . Front. Cell Infect. Microbiol.2, 131 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ikegami T , MakinoS . Rift valley fever vaccines . Vaccine27 ( Suppl. 4 ), D69 – D72 ( 2009 ).
   PubMedGoogle Scholar
• Kortekaas J . One health approach to Rift Valley fever vaccine development . Antiviral Res.106, 24 – 32 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Schmaljohn C , NicholST . Bunyaviridae . In : Fields Virology . KnipeDM, HowleyPM, GriffinDEet al. ( Eds ). Lippincott, Williams & Wilkins Philadelphia, PA, USA, 1741 – 1789 ( 2007 ).
   Google Scholar
• Strandin T , HepojokiJ, VaheriA . Cytoplasmic tails of bunyavirus Gn glycoproteins – could they act as matrix protein surrogates?Virology437 ( 2 ), 73 – 80 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Pettersson RF , AnderssonA, MelinL . Mapping a retention signal for Golgi localization of a viral spike protein complex . Cold Spring Harb. Symp. Quant. Biol.60, 147 – 155 ( 1995 ).
   PubMedGoogle Scholar
• Piper ME , SorensonDR, GerrardSR . Efficient cellular release of Rift Valley fever virus requires genomic RNA . PLoS ONE6 ( 3 ), e18070 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Carnec X , ErmonvalM, KreherF, FlamandM, BouloyM . Role of the cytosolic tails of Rift Valley fever virus envelope glycoproteins in viral morphogenesis . Virology448, 1 – 14 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Sherman MB , FreibergAN, HolbrookMR, WatowichSJ . Single-particle cryo-electron microscopy of Rift Valley fever virus . Virology387 ( 1 ), 11 – 15 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Freiberg AN , ShermanMB, MoraisMC, HolbrookMR, WatowichSJ . Three-dimensional organization of Rift Valley fever virus revealed by cryoelectron tomography . J. Virol.82 ( 21 ), 10341 – 10348 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Huiskonen JT , OverbyAK, WeberF, GrunewaldK . Electron cryo-microscopy and single-particle averaging of Rift Valley fever virus: evidence for GN-GC glycoprotein heterodimers . J. Virol.83 ( 8 ), 3762 – 3769 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Harmon B , SchudelBR, MaarDet al. Rift Valley fever virus strain MP-12 enters mammalian host cells via caveola-mediated endocytosis . J. Virol.86 ( 23 ), 12954 – 12970 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lozach PY , KuhbacherA, MeierRet al. DC-SIGN as a receptor for Phleboviruses . Cell Host Microbe10 ( 1 ), 75 – 88 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• De Boer SM , KortekaasJ, De HaanCA, RottierPJ, MoormannRJ, BoschBJ . Heparan sulfate facilitates Rift Valley fever virus entry into the cell . J. Virol.86 ( 24 ), 13767 – 13771 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Garry CE , GarryRF . Proteomics computational analyses suggest that the carboxyl terminal glycoproteins of Bunyaviruses are class II viral fusion protein (beta-penetrenes) . Theor. Biol. Med. Model.1, 1 – 10 ( 2004 ).
   PubMedGoogle Scholar
• Dessau M , ModisY . Crystal structure of glycoprotein C from Rift Valley fever virus . Proc. Natl Acad. Sci. USA110 ( 5 ), 1696 – 1701 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• De Boer SM , KortekaasJ, SpelL, RottierPJ, MoormannRJ, BoschBJ . Acid-activated structural reorganization of the Rift Valley fever virus Gc fusion protein . J. Virol.86 ( 24 ), 13642 – 13652 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Vialat P , BillecocqA, KohlA, BouloyM . The S segment of Rift Valley fever Phlebovirus (Bunyaviridae) carries determinants for attenuation and virulence in mice . J. Virol.74 ( 3 ), 1538 – 1543 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Ly HJ , IkegamiT . Rift Valley fever virus NSs protein functions and the similarity to other Bunyavirus NSs proteins . Virol. J.13, 118 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Ikegami T , NarayananK, WonS, KamitaniW, PetersCJ, MakinoS . Dual functions of Rift Valley fever virus NSs protein: inhibition of host mRNA transcription and post-transcriptional downregulation of protein kinase PKR . Ann. NY Acad. Sci.1171 ( Suppl. 1 ), E75 – E85 ( 2009 ).
   PubMedGoogle Scholar
• Le May N , MansurogluZ, LegerPet al. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells . PLoS Pathog.4 ( 1 ), e13 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Swanepoel R , BlackburnNK . Demonstration of nuclear immunofluorescence in Rift Valley fever infected cells . J. Gen. Virol.34 ( 3 ), 557 – 561 ( 1977 ).
   PubMedGoogle Scholar
• Yadani FZ , KohlA, PrehaudC, BillecocqA, BouloyM . The carboxy-terminal acidic domain of Rift Valley fever virus NSs protein is essential for the formation of filamentous structures but not for the nuclear localization of the protein . J. Virol.73 ( 6 ), 5018 – 5025 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Bird BH , AlbarinoCG, NicholST . Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease . Virology362 ( 1 ), 10 – 15 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Meegan JM . The Rift Valley fever epizootic in Egypt 1977–78. 1. Description of the epizzotic and virological studies . Trans. R Soc. Trop. Med. Hyg.73 ( 6 ), 618 – 623 ( 1979 ).
   PubMed Web of Science ®Google Scholar
• Hoogstraal H , MeeganJM, KhalilGM, AdhamFK . The Rift Valley fever epizootic in Egypt 1977–78. 2. Ecological and entomological studies . Trans. R Soc. Trop. Med. Hyg.73 ( 6 ), 624 – 629 ( 1979 ).
   PubMed Web of Science ®Google Scholar
• Woods CW , KarpatiAM, GreinTet al. An outbreak of Rift Valley fever in northeastern Kenya, 1997–98 . Emerg. Infect. Dis.8 ( 2 ), 138 – 144 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Mundel B , GearJ . Rift Valley fever; I. The occurrence of human cases in Johannesburg . S. Afr. Med. J.25 ( 44 ), 797 – 800 ( 1951 ).
   PubMedGoogle Scholar
• Joubert JD , FergusonAL, GearJ . Rift Valley fever in South Africa: 2. The occurrence of human cases in the orange free state, the north-western Cape province, the western and southern Transvaal. A. Epidemiological and clinical findings . S. Afr. Med. J.25 ( 48 ), 890 – 891 ( 1951 ).
   PubMedGoogle Scholar
• Strausbaugh LJ , LaughlinLW, MeeganJM, WattenRH . Clinical studies on Rift Valley fever, Part I. Acute febrile and hemorrhagic-like diseases . J. Egypt. Public Health Assoc.53 ( 3–4 ), 181 – 182 ( 1978 ).
   PubMedGoogle Scholar
• Madani TA , Al-MazrouYY, Al-JeffriMHet al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics . Clin. Infect. Dis.37 ( 8 ), 1084 – 1092 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Findlay GM , DaubneyR . The virus of rift valley fever or enzootic hepatitis . Lancet221, 1350 – 1351 ( 1931 ).
   Google Scholar
• Kahlon SS , PetersCJ, LeducJet al. Severe Rift Valley fever may present with a characteristic clinical syndrome . Am. J. Trop. Med. Hyg.82 ( 3 ), 371 – 375 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Laughlin LW , MeeganJM, StrausbaughLJ, MorensDM, WattenRH . Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness . Trans. R. Soc. Trop. Med. Hyg.73 ( 6 ), 630 – 633 ( 1979 ).
   PubMed Web of Science ®Google Scholar
• Yassin W . Clinico-pathological picture in five human cases died with Rift Valley fever . J. Egypt. Public Health Assoc.53 ( 3–4 ), 191 – 193 ( 1978 ).
   PubMedGoogle Scholar
• Swanepoel R , ManningB, WattJA . Fatal Rift Valley fever of man in Rhodesia . Cent. Afr. J. Med.25 ( 1 ), 1 – 8 ( 1979 ).
   PubMedGoogle Scholar
• Al-Hazmi M , AyoolaEA, AbdurahmanMet al. Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans . Clin. Infect. Dis.36 ( 3 ), 245 – 252 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab KS , El BazLM, El-TayebEM, OmarH, OssmanMA, YasinW . Rift Valley fever virus infections in Egypt: pathological and virological findings in man . Trans. R. Soc. Trop. Med. Hyg.72 ( 4 ), 392 – 396 ( 1978 ).
   PubMed Web of Science ®Google Scholar
• Alrajhi AA , Al-SemariA, Al-WatbanJ . Rift Valley fever encephalitis . Emerg. Infect. Dis.10 ( 3 ), 554 – 555 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Maar SA , SwanepoelR, GelfandM . Rift Valley fever encephalitis. A description of a case . Cent. Afr. J. Med.25 ( 1 ), 8 – 11 ( 1979 ).
   PubMedGoogle Scholar
• Van Velden DJ , MeyerJD, OlivierJ, GearJH, McintoshB . Rift Valley fever affecting humans in South Africa: a clinicopathological study . S. Afr. Med. J.51 ( 24 ), 867 – 871 ( 1977 ).
   PubMed Web of Science ®Google Scholar
• El-Shinnawi BM , SobhyF, El-ZawahryA . Laboratory findings in some cases of Rift Valley fever: histopathological haematological, and biochemical . J. Egypt. Public Health Assoc.53 ( 3–4 ), 187 – 189 ( 1978 ).
   PubMedGoogle Scholar
• Deutman AF , KlompHJ . Rift Valley fever retinitis . Am. J. Ophthalmol.92 ( 1 ), 38 – 42 ( 1981 ).
   PubMed Web of Science ®Google Scholar
• Siam AL , MeeganJM, GharbawiKF . Rift Valley fever ocular manifestations: observations during the 1977 epidemic in Egypt . Br. J. Ophthalmol.64 ( 5 ), 366 – 374 ( 1980 ).
   PubMed Web of Science ®Google Scholar
• Siam AL , MeeganJM . Ocular disease resulting from infection with Rift Valley fever virus . Trans. R Soc. Trop. Med. Hyg.74 ( 4 ), 539 – 541 ( 1980 ).
   PubMed Web of Science ®Google Scholar
• Schrire L . Macular changes in Rift Valley fever . S. Afr. Med. J.25 ( 50 ), 926 – 930 ( 1951 ).
   PubMedGoogle Scholar
• Freed I . Rift Valley fever in man, complicated by retinal changes and loss of vision . S. Afr. Med. J.25 ( 50 ), 930 – 932 ( 1951 ).
   PubMedGoogle Scholar
• Ayoub M , BarhomaG, ZaghlolI . Ocular manifestations of Rift Valley fever . Bull. Ophthalmol. Soc. Egypt71 ( 75 ), 125 – 133 ( 1978 ).
   PubMedGoogle Scholar
• Al-Hazmi A , Al-RajhiAA, AbboudEBet al. Ocular complications of Rift Valley fever outbreak in Saudi Arabia . Ophthalmology112 ( 2 ), 313 – 318 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Behara R , ReauN . Updates on hepatitis C virus therapy in the direct-acting antiviral era . Curr. Opin. Gastroenterol.33 ( 3 ), 115 – 119 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Maina G , MillJ, Chaw-KantJ, CaineV . A systematic review of best practices in HIV care . J. HIV AIDS Soc. Serv.15 ( 1 ), 114 – 126 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Arts EJ , HazudaDJ . HIV-1 antiretroviral drug therapy . Cold Spring Harb. Perspect. Med.2 ( 4 ), a007161 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Caplen H , PetersCJ, BishopDH . Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development . J. Gen. Virol.66 ( Pt 10 ), 2271 – 2277 ( 1985 ).
   PubMed Web of Science ®Google Scholar
• Kilgore PE , KsiazekTG, RollinPEet al. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin . Clin. Infect. Dis.24 ( 4 ), 718 – 722 ( 1997 ).
   PubMed Web of Science ®Google Scholar
• Mccormick JB , KingIJ, WebbPAet al. Lassa fever. Effective therapy with ribavirin . N. Engl. J. Med.314 ( 1 ), 20 – 26 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Monath TP . Treatment of yellow fever . Antiviral Res.78 ( 1 ), 116 – 124 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Kirsi JJ , NorthJA, MckernanPAet al. Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent . Antimicrob. Agents Chemother.24 ( 3 ), 353 – 361 ( 1983 ).
   PubMed Web of Science ®Google Scholar
• Sidwell RW , HuffmanJH, BarnettBB, PifatDY . In vitro and in vivo Phlebovirus inhibition by ribavirin . Antimicrob. Agents Chemother.32 ( 3 ), 331 – 336 ( 1988 ).
   PubMed Web of Science ®Google Scholar
• Kende M , AlvingCR, RillWL, SwartzGMJr, CanonicoPG . Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice . Antimicrob. Agents Chemother.27 ( 6 ), 903 – 907 ( 1985 ).
   PubMed Web of Science ®Google Scholar
• Reed C , LinK, WilhelmsenCet al. Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development . PLoS Negl. Trop. Dis.7 ( 4 ), e2156 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Kende M , LuptonHW, RillWL, GibbsP, LevyHB, CanonicoPG . Ranking of prophylactic efficacy of poly(ICLC) against Rift Valley fever virus infection in mice by incremental relative risk of death . Antimicrob. Agents Chemother.31 ( 8 ), 1194 – 1198 ( 1987 ).
   PubMed Web of Science ®Google Scholar
• Peters CJ , ReynoldsJA, SloneTW, JonesDE, StephenEL . Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator . Antiviral Res.6 ( 5 ), 285 – 297 ( 1986 ).
   PubMed Web of Science ®Google Scholar
• Furuta Y , TakahashiK, Kuno-MaekawaMet al. Mechanism of action of T-705 against influenza virus . Antimicrob. Agents Chemother.49 ( 3 ), 981 – 986 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Kiso M , TakahashiK, Sakai-TagawaYet al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses . Proc. Natl Acad. Sci. USA107 ( 2 ), 882 – 887 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Furuta Y , TakahashiK, ShirakiKet al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections . Antiviral Res.82 ( 3 ), 95 – 102 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Sleeman K , MishinVP, DeydeVM, FurutaY, KlimovAI, GubarevaLV . In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses . Antimicrob. Agents Chemother.54 ( 6 ), 2517 – 2524 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Furuta Y , GowenBB, TakahashiK, ShirakiK, SmeeDF, BarnardDL . Favipiravir (T-705), a novel viral RNA polymerase inhibitor . Antiviral Res.100 ( 2 ), 446 – 454 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Safronetz D , RosenkeK, WestoverJBet al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset . Sci. Rep.5, 14775 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Gowen BB , WongMH, JungKHet al. In vitro and in vivo activities of T-705 against arenavirus and Bunyavirus infections . Antimicrob. Agents Chemother.51 ( 9 ), 3168 – 3176 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Jochmans D , Van NieuwkoopS, SmitsSL, NeytsJ, FouchierRA, Van Den HoogenBG . Antiviral activity of favipiravir (T-705) against a broad range of Paramyxoviruses in vitro and against human metapneumovirus in hamsters . Antimicrob. Agents Chemother.60 ( 8 ), 4620 – 4629 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Wolf MC , FreibergAN, ZhangTet al. A broad-spectrum antiviral targeting entry of enveloped viruses . Proc. Natl Acad. Sci. USA107 ( 7 ), 3157 – 3162 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Safronetz D , FalzaranoD, ScottDP, FurutaY, FeldmannH, GowenBB . Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome . Antimicrob. Agents Chemother.57 ( 10 ), 4673 – 4680 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Mendenhall M , RussellA, JuelichTet al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture . Antimicrob. Agents Chemother.55 ( 2 ), 782 – 787 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mendenhall M , RussellA, SmeeDFet al. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever . PLoS Negl. Trop. Dis.5 ( 10 ), e1342 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Julander JG , ShaferK, SmeeDF, MorreyJD, FurutaY . Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106 . Antimicrob. Agents Chemother.53 ( 1 ), 202 – 209 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Julander JG , SmeeDF, MorreyJD, FurutaY . Effect of T-705 treatment on western equine encephalitis in a mouse model . Antiviral Res.82 ( 3 ), 169 – 171 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Rocha-Pereira J , JochmansD, DallmeierK, LeyssenP, NascimentoMS, NeytsJ . Favipiravir (T-705) inhibits in vitro norovirus replication . Biochem. Biophys. Res. Commun.424 ( 4 ), 777 – 780 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Furuta Y , TakahashiK, FukudaYet al. In vitro and in vivo activities of anti-influenza virus compound T-705 . Antimicrob. Agents Chemother.46 ( 4 ), 977 – 981 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Gowen BB , SmeeDF, WongMHet al. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin . PLoS ONE3 ( 11 ), e3725 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Gowen BB , JulanderJG, LondonNRet al. Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever . Virol. J.7, 240 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Oestereich L , RiegerT, NeumannMet al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean–Congo hemorrhagic fever . PLoS Negl. Trop. Dis.8 ( 5 ), e2804 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Scharton D , BaileyKW, VestZet al. Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment . Antiviral Res.104, 84 – 92 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Caroline AL , PowellDS, BethelLM, OuryTD, ReedDS, HartmanAL . Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley fever . PLoS Negl. Trop. Dis.8 ( 4 ), e2790 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Nelson KM , DahlinJL, BissonJ, GrahamJ, PauliGF, WaltersMA . The essential medicinal chemistry of curcumin . J. Med. Chem.60 ( 5 ), 1620 – 1637 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Narayanan A , Kehn-HallK, SeninaSet al. Curcumin inhibits Rift Valley fever virus replication in human cells . J. Biol. Chem.287 ( 40 ), 33198 – 33214 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Garcia S , CranceJM, BillecocqAet al. Quantitative real-time PCR detection of Rift Valley fever virus and its application to evaluation of antiviral compounds . J. Clin. Microbiol.39 ( 12 ), 4456 – 4461 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Broce S , HensleyL, SatoTet al. Biochemical and biophysical characterization of cell-free synthesized Rift Valley fever virus nucleoprotein capsids enables in vitro screening to identify novel antivirals . Biol. Direct11, 25 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Ellenbecker M , LanchyJM, LodmellJS . Inhibition of Rift Valley fever virus replication and perturbation of nucleocapsid-RNA interactions by suramin . Antimicrob. Agents Chemother.58 ( 12 ), 7405 – 7415 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ellenbecker M , LanchyJM, LodmellJS . Identification of Rift Valley fever virus nucleocapsid protein-RNA binding inhibitors using a high-throughput screening assay . J. Biomol. Screen.17 ( 8 ), 1062 – 1070 ( 2012 ).
   PubMedGoogle Scholar
• Ellenbecker M , SearsL, LiP, LanchyJM, LodmellJS . Characterization of RNA aptamers directed against the nucleocapsid protein of Rift Valley fever virus . Antiviral Res.93 ( 3 ), 330 – 339 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Warren TK , WellsJ, PanchalRGet al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430 . Nature508 ( 7496 ), 402 – 405 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Taylor R , KotianP, WarrenTet al. BCX4430 – a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease . J. Infect. Public Health9 ( 3 ), 220 – 226 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Islam MK , BaudinM, ErikssonJet al. High-throughput screening using a whole-cell virus replication reporter gene assay to identify inhibitory compounds against Rift Valley fever virus infection . J. Biomol. Screen.21 ( 4 ), 354 – 362 ( 2016 ).
   PubMedGoogle Scholar
• Vigant F , SantosNC, LeeB . Broad-spectrum antivirals against viral fusion . Nat. Rev. Microbiol.13 ( 7 ), 426 – 437 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hollmann A , CastanhoMA, LeeB, SantosNC . Singlet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors . Biochem. J.459 ( 1 ), 161 – 170 ( 2014 ).
   PubMedGoogle Scholar
• Vigant F , LeeJ, HollmannAet al. A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion . PLoS Pathog.9 ( 4 ), e1003297 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Benedict A , BansalN, SeninaSet al. Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection . Front. Microbiol.6, 676 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Randow F , LehnerPJ . Viral avoidance and exploitation of the ubiquitin system . Nat. Cell Biol.11 ( 5 ), 527 – 534 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Chen D , FrezzaM, SchmittS, KanwarJ, DouQP . Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives . Curr. Cancer Drug Targets11 ( 3 ), 239 – 253 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Keck F , AmayaM, Kehn-HallK, RobertsB, BaileyC, NarayananA . Characterizing the effect of Bortezomib on Rift Valley Fever virus multiplication . Antiviral Res.120, 48 – 56 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Aman MJ , KinchMS, WarfieldKet al. Development of a broad-spectrum antiviral with activity against Ebola virus . Antiviral Res.83 ( 3 ), 245 – 251 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Moy RH , GoldB, MollestonJMet al. Antiviral autophagy restricts Rift Valley fever virus infection and is conserved from flies to mammals . Immunity40 ( 1 ), 51 – 65 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Atkins C , EvansCW, NordinBet al. Global human-kinase screening identifies therapeutic host targets against influenza . J. Biomol. Screen.19 ( 6 ), 936 – 946 ( 2014 ).
   PubMedGoogle Scholar
• Dyall J , ColemanCM, HartBJet al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection . Antimicrob. Agents Chemother.58 ( 8 ), 4885 – 4893 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Reeves PM , BommariusB, LebeisSet al. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases . Nat. Med.11 ( 7 ), 731 – 739 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Filone CM , HannaSL, CainoMC, BambinaS, DomsRW, CherryS . Rift valley fever virus infection of human cells and insect hosts is promoted by protein kinase C epsilon . PLoS ONE5 ( 11 ), e15483 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Bell TM , EspinaV, SeninaSet al. Rapamycin modulation of p70 S6 kinase signaling inhibits Rift Valley fever virus pathogenesis . Antiviral Res.143, 162 – 175 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Nuss JE , Kehn-HallK, BenedictAet al. Multi-faceted proteomic characterization of host protein complement of Rift Valley fever virus virions and identification of specific heat shock proteins, including HSP90, as important viral host factors . PLoS ONE9 ( 5 ), e93483 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Patil SA , PatilV, PatilR, BeamanK, PatilSA . Identification of novel 5,6-dimethoxyindan-1-one derivatives as antiviral agents . Med. Chem. doi:10.2174/1573406413666170330094822 ( 2017 ) ( Epub ahead of print ).
   PubMedGoogle Scholar
• Moser TS , SchiefferD, CherryS . AMP-activated kinase restricts Rift Valley fever virus infection by inhibiting fatty acid synthesis . PLoS Pathog.8 ( 4 ), e1002661 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ilinykh PA , TigabuB, IvanovAet al. Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription . J. Biol. Chem.289 ( 33 ), 22723 – 22738 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Modrof J , MuhlbergerE, KlenkHD, BeckerS . Phosphorylation of VP30 impairs ebola virus transcription . J. Biol. Chem.277 ( 36 ), 33099 – 33104 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Nekhai S , JerebtsovaM, JacksonA, SoutherlandW . Regulation of HIV-1 transcription by protein phosphatase 1 . Curr. HIV Res.5 ( 1 ), 3 – 9 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Baer A , ShafagatiN, BenedictAet al. Protein phosphatase-1 regulates Rift Valley fever virus replication . Antiviral Res.127, 79 – 89 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Liu SY , AliyariR, ChikereKet al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol . Immunity38 ( 1 ), 92 – 105 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Olas B . Hydrogen sulfide in signaling pathways . Clin. Chim. Acta439, 212 – 218 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Wu D , HuQ, ZhuY . Therapeutic application of hydrogen sulfide donors: the potential and challenges . Front. Med.10 ( 1 ), 18 – 27 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Rose P , DymockBW, MoorePK . GYY4137, a novel water-soluble, H2S-releasing molecule . Methods Enzymol.554, 143 – 167 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Li H , MaY, EscaffreOet al. Role of hydrogen sulfide in paramyxovirus infections . J. Virol.89 ( 10 ), 5557 – 5568 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Ivanciuc T , SbranaE, AnsarMet al. Hydrogen sulfide is an antiviral and antiinflammatory endogenous gasotransmitter in the airways. Role in respiratory syncytial virus infection . Am. J. Respir. Cell Mol. Biol.55 ( 5 ), 684 – 696 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Ibazhanov N , EscaffreO, FreibergAN, GarofaloRP, CasolaA . Broad-range antiviral activity of hydrogen sulfide against highly pathogenic RNA viruses . Sci. Rep.7, 41029 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Boutros M , HeigwerF, LauferC . Microscopy-based high-content screening . Cell163 ( 6 ), 1314 – 1325 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Mudhasani R , KotaKP, RettererCet al. High-content image-based screening of a signal transduction pathway inhibitor small-molecule library against highly pathogenic RNA viruses . J. Biomol. Screen.20 ( 1 ), 141 – 152 ( 2015 ).
   PubMedGoogle Scholar
• Mudhasani R , KotaKP, RettererC, TranJP, WhitehouseCA, BavariS . High content image-based screening of a protease inhibitor library reveals compounds broadly active against Rift Valley fever virus and other highly pathogenic RNA viruses . PLoS Negl. Trop. Dis.8 ( 8 ), e3095 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hackett BA , YasunagaA, PandaDet al. RNASEK is required for internalization of diverse acid-dependent viruses . Proc. Natl Acad. Sci. USA112 ( 25 ), 7797 – 7802 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Harmon B , BirdSW, SchudelBR, HatchAV, RasleyA, NegreteOA . A genome-wide RNA interference screen identifies a role for WNT/beta-catenin signaling during Rift Valley fever virus infection . J. Virol.90 ( 16 ), 7084 – 7097 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Camini FC , Da Silva CaetanoCC, AlmeidaLT, De Brito MagalhaesCL . Implications of oxidative stress on viral pathogenesis . Arch. Virol.162 ( 4 ), 907 – 917 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Narayanan A , PopovaT, TurellMet al. Alteration in superoxide dismutase 1 causes oxidative stress and p38 MAPK activation following RVFV infection . PLoS ONE6 ( 5 ), e20354 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Panchal RG , ReidSP, TranJPet al. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity . Antiviral Res.93 ( 1 ), 23 – 29 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kilby JM , HopkinsS, VenettaTMet al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry . Nat. Med.4 ( 11 ), 1302 – 1307 ( 1998 ).
   PubMed Web of Science ®Google Scholar
• Wild C , GreenwellT, MatthewsT . A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion . AIDS Res. Hum. Retroviruses9 ( 11 ), 1051 – 1053 ( 1993 ).
   PubMed Web of Science ®Google Scholar
• Hrobowski YM , GarryRF, MichaelSF . Peptide inhibitors of dengue virus and West Nile virus infectivity . Virol. J.2, 49 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Schmidt AG , YangPL, HarrisonSC . Peptide inhibitors of flavivirus entry derived from the E protein stem . J. Virol.84 ( 24 ), 12549 – 12554 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Schmidt AG , YangPL, HarrisonSC . Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate . PLoS Pathog.6 ( 4 ), e1000851 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Costin JM , JenwitheesukE, LokSMet al. Structural optimization and de novo design of dengue virus entry inhibitory peptides . PLoS Negl. Trop. Dis.4 ( 6 ), e721 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Porotto M , CartaP, DengYet al. Molecular determinants of antiviral potency of paramyxovirus entry inhibitors . J. Virol.81 ( 19 ), 10567 – 10574 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Koehler JW , SmithJM, RipollDRet al. A fusion-inhibiting peptide against Rift Valley fever virus inhibits multiple, diverse viruses . PLoS Negl. Trop. Dis.7 ( 9 ), e2430 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Chevalier V , PepinM, PleeL, LancelotR . Rift Valley fever – a threat for Europe?Euro Surveill.15 ( 10 ), 19506 ( 2010 ).
   PubMedGoogle Scholar
• Hartley DM , RinderknechtJL, NippTLet al. Potential effects of Rift Valley fever in the United States . Emerg. Infect. Dis.17 ( 8 ), e1 ( 2011 ).
   PubMedGoogle Scholar
• Rift Valley fever – China: ex Angola . www.promedmail.org/post/20160725.4368585 .
   Google Scholar
• Rift Valley fever, human – France: ex Zimbabwe (Mashonaland east). www.promedmail.org/direct.php?id=916603 .
   Google Scholar
• First report . www.promedmail.org/direct.php?id=916603 .
   Google Scholar
• WHO . Workshop on prioritization of pathogens : blueprint for R&D preparedness and response to public health emergencies due to highly infectious pathogens ( 2015 ).
   Google Scholar
• WHO publishes list of top emerging diseases likely to cause major epidemics . www.who.int/medicines/ebola-treatment/WHO-list-of-top-emerging-diseases/en/ .
   Google Scholar
• Rift Valley fever – France ex Mali, 2015 . www.promedmail.org/post/20160506.4207036 .
   Google Scholar
• Bird BH , NicholST . Breaking the chain: Rift Valley fever virus control via livestock vaccination . Curr. Opin. Virol.2 ( 3 ), 315 – 323 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Kende M . Prophylactic and therapeutic efficacy of poly(I, C)-LC against Rift Valley fever virus infection in mice . J. Biol. Response Mod.4 ( 5 ), 503 – 511 ( 1985 ).
   PubMedGoogle Scholar